Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of signed informed consent prior to study data collection
Patient with COPD aged 40 years or older
Patient prescribed (or already receiving the disposable Respimat SMI and switched to) one of the following re-usable Respimat SMI products per the standard clinical practice: Spiriva 2.5 microgram inhalation solution; (2) Striverdi 2.5 microgram inhalation solution; and (3) Spiolto 2.5 microgram / 2.5 microgram inhalation solution
Patient unlikely to change their Respimat therapy during the 4-6 week observation period (in the opinion of the investigator)
You may not be if
Patient using a disposable Respimat SMI product during the study period
Patient who have had a severe COPD exacerbation requiring hospitalisation in the immediate 3 months prior to study entry
Patient participating in a clinical trial or any other non-interventional study of a drug or device at the time of enrolment
Visual, cognitive, motor or health impairment that, as judged by the investigator, may cause concern regarding the patient's ability to complete the questionnaires
Patient not fluent and literate in one of the main languages of the country
